Professional research reports powered by Noah AI — grounded in 100M+ sources including PubMed, clinical trials, guidelines, and patents.
The autoimmune patent cliff, unmet clinical need, and novel mechanisms are driving record M&A activity from 2026–2029.
Four issues remain: two reference mismatches, asset misclassification in Table 1, and missing oncology-to-autoimmune safety caveat.
Autoimmune BD surges as B-cell therapies, FcRn inhibitors, and CAR-T reshape deal-making and clinical strategy through 2029.
Autoimmune deal momentum surges, driven by novel modalities, China innovation, and pivotal 2026–2029 clinical catalysts.
Off-the-shelf CAR-T excels in production yet faces safety, durability and global approval hurdles in 2026.
Solid tumor CAR-T advances with logic-gated designs, CLDN18.2 randomized success, and brain tumor breakthroughs—yet durable remissions remain rare.
In vivo CAR-T therapies reprogram T cells inside patients via viral or nanoparticle vectors, eliminating ex vivo manufacturing.
CD3 bispecific T-cell engagers now deliver off-the-shelf, T-cell–mediated tumor killing across hematologic and select solid tumor indications.
Oncology radiopharmaceuticals are rapidly maturing precision therapies, expanding from NET and prostate cancer into broader solid tumor indications.
B7-H3 ADCs show robust clinical activity across multiple solid tumors, with I-DXd under FDA Priority Review, nearing first potential approval.
TROP2 ADCs transform solid tumor treatment via three approved agents, distinct safety profiles, and emerging biomarker-driven combination strategies in 2026.
China's oncology innovation reshapes global pharma pipelines through massive licensing deals in ADCs and bispecific antibodies.
Next-gen ADCs upgrade structures, expand targets and face multiple clinical challenges.
2026 oncology M&A surges driven by patent cliffs, novel modalities and booming Chinese biotech licensing.
Stage, mechanism and biomarkers shape oncology asset risks and deal values.
Four core clinical factors jointly determine rNPV and transaction pricing of oncology assets.
BsAb transactions surge amid mature platforms, validated dual targets and cross-field expansion.
ADC deals surge driven by payload innovation, patent risks and rising clinical value.
Validated RPT booms with massive pharma M&A yet faces multiple clinical and supply hurdles.
BEP/EP regimens cure TGCTs; prioritize dose intensity, fertility, and long-term toxicity care.